LiJY, KuickR, ThompsonRC, et al.: Arcuate nucleus transcriptome profiling identifies ankyrin repeat and suppressor of cytokine signalling box-containing protein 4 as a gene regulated by fasting in central nervous system feeding circuits. J Neuroendocrinol, 2005; 17:394–404.
2.
DerbenevAV, ZsombokA: Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity. Semin Immunopathol, 2016; 38:397–406.
3.
WuZY, LiH, LiJR, LvXQ, JiangJD, PengZG: Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. Eur J Pharmacol, 2019; 853:111–120.
4.
ScholtesC, DiazO, IcardV, et al.: Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol, 2008; 48:192–199.
5.
KanSL, NingGZ, ChenLX, ZhouY, SunJC, FengSQ: Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: a meta-analysis. Medicine (Baltimore), 2016; 95:e2679.
6.
Toth-ManikowskiSM, FrancisJM, GautamA, GordonCE: Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant, 2016; 30:1090–1096.
7.
Vila CuencaM, HordijkPL, VervloetMG: Most exposed: the endothelium in chronic kidney disease. Nephrol Dial Transplant, 2019 [Epub ahead of print]; DOI: 10.1093/ndt/gfz055.
8.
YamagishiS, MatsuiT, NakamuraK, TakeuchiM: Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React, 2005; 27:189–195.
9.
HanJ, JiangDM, YeY, DuCQ, YangJ, HuSJ: Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats. Mol Med Rep, 2016; 13:3787–3796.
10.
BaumgartnerL, LamK, LaiJ, et al.: Effectiveness of melatonin for the prevention of intensive care unit delirium. Pharmacotherapy, 2019; 39:280–287.
11.
ThomR, BuiM, RosnerB, et al.: Ramelteon is not associated with improved outcomes among critically ill delirious patients: a single-center retrospective cohort study. Psychosomatics, 2018 [Epub ahead of print]; DOI: 10.1016/j.psym.2018.07.015.
12.
HayakawaK, KatoTA, KohjiroM, MonjiA, KanbaS: Minocycline, a microglial inhibitor, diminishes terminal patients' delirium?. Am J Geriatr Psychiatry, 2014; 22:314–315.
13.
JallehR, KohK, ChoiB, LiuE, MaddisonJ, HutchinsonMR: Role of microglia and toll-like receptor 4 in the pathophysiology of delirium. Med Hypotheses, 2012; 79:735–739.
14.
KelsoML, ScheffNN, ScheffSW, PaulyJR: Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury. Neurosci Lett, 2011; 488:60–64.
15.
DiamondMP: Reduction of postoperative adhesion development. Fertil Steril, 2016; 106:994–997.e1.
JinX, RenS, MacarakE, RosenbloomJ: Pathobiological mechanisms of peritoneal adhesions: the mesenchymal transition of rat peritoneal mesothelial cells induced by TGF-β1 and IL-6 requires activation of Erk1/2 and Smad2 linker region phosphorylation. Matrix Biol, 2016; 51:55–64.
18.
ZhouX, PatelD, SenS, et al.: Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis. J Vasc Surg, 2017; 65:1161–1169.
19.
El-HamolyT, El-DensharyES, SaadSM, El-GhazalyMA: 3-aminobenzamide, a poly (ADP ribose) polymerase inhibitor, enhances wound healing in whole body gamma irradiated model. Wound Repair Regen, 2015; 23:672–684.
20.
AhmadA, OlahG, HerndonDN, SzaboC: The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury. Br J Pharmacol, 2018; 175:232–245.
21.
KönigS, Probst-KepperM, ReinlT, et al.: First insight into the kinome of human regulatory T cells. PLoS One, 2012; 7:e40896.
22.
WangW, OhS, KoesterM, et al.: Enhanced megakaryopoiesis and platelet activity in hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-deficient mice. Circ Cardiovasc Genet, 2016; 9:213–222.
23.
Vinué Á, Martínez-HervásS, Herrero-CerveraA, Sánchez-GarcíaV, Andrés-BlascoI, PiquerasL: Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus. Transl Res, 2019; 203:31–48.
24.
BerthautI, BachirD, KottiS, et al.: Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood, 2017; 130:2354–2356.
25.
SahooLK, KulluBK, PatelS, et al.: Study of seminal fluid parameters and fertility of male sickle cell disease patients and potential impact of hydroxyurea treatment. J Assoc Physicians India, 2017; 65:22–25.
26.
BerthautI, GuignedouxG, Kirsch-NoirF, et al.: Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica, 2008; 93:988–993.
27.
NelsonEA, WalkerSR, WeisbergE, et al.: The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood, 2011; 117:3421–3429.
28.
ŚwierkotJ, NowakB, CzarnyA, et al.: The activity of JAK/STAT and NF-κB in patients with rheumatoid arthritis. Adv Clin Exp Med, 2016; 25:709–717.
29.
ThomasS, FisherKH, SnowdenJA, DansonSJ, BrownS, ZeidlerMP: Methotrexate is a JAK/STAT pathway inhibitor. PLoS One, 2015; 10:e0130078.
30.
LeviteM: Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol, 2016; 216:42–89.
31.
KimH, BangJ, ChangHW, et al.: Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol, 2012; 678:55–60.
32.
PanYJ, WangWH, HuangTY, et al.: Quetiapine ameliorates collagen-induced arthritis in mice via the suppression of the AKT and ERK signaling pathways. Inflamm Res, 2018; 67:847–861.
33.
BandaDM, NuñezNN, BurnsideMA, BradshawKM, DavidSS: Repair of 8-oxoG: a mismatches by the MUTYH glycosylase: mechanism, metals and medicine. Free Radic Biol Med, 2017; 107:202–215.
34.
MazouziA, BattistiniF, MoserSC, et al.: Repair of UV-induced DNA damage independent of nucleotide excision repair is masked by MUTYH. Mol Cell, 2017; 68:797–807.e7.
35.
XiaJ, YangL, DongL, et al.: Cefminox, a dual agonist of prostacyclin receptor and peroxisome proliferator-activated receptor-gamma identified by virtual screening, has therapeutic efficacy against hypoxia-induced pulmonary hypertension in rats. Front Pharmacol, 2018; 9:134.
36.
ZanasiA, MazzoliniM, KantarA: A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med, 2017; 12:7.
37.
KernKU, Schwickert-NieswandtM, MaihöfnerC, GaulC: Topical ambroxol 20% for the treatment of classical trigeminal neuralgia—a new option? Initial clinical case observations. Headache, 2019; 59:418–429.
38.
MaihöfnerC, SchneiderS, BialasP, et al.: Successful treatment of complex regional pain syndrome with topical ambroxol: a case series. Pain Manag, 2018; 8:427–436.
39.
WeiserT, WilsonN: Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. Mol Pharmacol, 2002; 62:433–438.
